Cardiovascular adverse events associated with cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone with or without rituximab ((R)-CDOP) in non-Hodgkin's lymphoma: A systematic review and meta-analysis
Background: The (R)-CDOP combination regimen, based on pegylated liposomal doxorubicin, is increasingly used for elderly patients with non-Hodgkin's lymphoma. However, the cardiotoxicity and efficacy of the (R)-CDOP regimen compared with conventional anthracyclines have not been demonstrated in...
Saved in:
Main Authors: | Bin Lu (Author), Longfei Shen (Author), Ying Ma (Author), Jia Qi (Author), Yulin Li (Author), Zhihao Wang (Author), Lu Han (Author), Ming Zhong (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pegylated liposomal doxorubicin in ovarian cancer
by: Robert Strother, et al.
Published: (2009) -
Pegylated liposomal doxorubicin in the management of ovarian cancer
by: Gabriella Ferrandina, et al.
Published: (2010) -
Pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia
by: Joana Moreira-Barros, et al.
Published: (2018) -
Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies
by: S. Yost, et al.
Published: (2019) -
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
by: Zhen Yuan, et al.
Published: (2021)